Low dose Unfractionated Heparin Prophylaxis is a Safe Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome After Myeloablative Adult Allogenic Stem Cell Transplant

Maria Sola#,1,2, Valkal Bhatt#,1, Meighan Palazzo1, Kathleen E. Cavalier1, Sean M. Devlin3, Molly Maloy1, Juliet N. Barker1,4, Hugo Castro-Malaspina1,4, David Chung1,4, Parastoo B. Dahi1,4, Ann A. Jakubowski1,4, Heather Landau1,4, Esperanza B Papadopoulos1,4, Miguel-Angel Perales1,4, Craig Sauter1,4, Roni Tamari1,4, Nancy A. Kernan5, Sergio Giralt1,4, James W. Young1,4, Jenna D. Goldberg1,4, Doris M. Ponce1,4

1Adult Bone Marrow Transplant Service, Division of Hematology/Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
2Hematology Department, Hospital General Universitario Morales Meseguer, Murcia, Spain
3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
4Weill Cornell Medical College; New York, NY
5Bone Marrow Transplant Service, Department of Pediatrics

Abstract

Hepatic sinusoidal obstruction syndrome (SOS) is a serious complication after allogeneic stem cell transplantation (allo-HCT). However, there is no uniform consensus on the optimal strategy for SOS prevention. Ursodeoxycholic acid is the most used regimen, even though its administration is challenging in recipients unable to tolerate oral medication. Defibrotide was recently studied in a phase 3 trial, but enrollment was stopped early due to futility. Low dose unfractionated heparin (UFH) is an alternative strategy. However, its efficacy is reputed but unproven increased risk of bleeding has not been fully established. We evaluated 514 adult allo-HCT recipients who received SOS prophylaxis with low dose UFH. Bleeding complications occurred in 12 patients 2.3% of patients of which only 2 (0.4%) had significant grade 3 bleeding. Only 14 patients were diagnosed with hepatic SOS. Univariate analysis showed that day 100 SOS was higher in recipients of unmodified grafts when compared to CD34+ selected ex vivo T-cell depleted grafts.
(p ≤ 0.001), and patients with hepatitis B and/or C exposure pre-HCT (p = 0.028). Overall, UFH was well tolerated and associated with a low incidence of subsequent hepatic SOS. Low dose UFH prophylaxis can be considered in select patients who cannot tolerate oral ursodiol.

Keywords
sinusoidal obstructive syndrome; unfractionated heparin; myeloablative adult allogenic stem cell transplant

INTRODUCTION

Hepatic sinusoidal obstruction syndrome (SOS) is a serious complication of hematopoietic stem cell transplant (HCT), associated with a high mortality risk\textsuperscript{1–3}. The incidence of SOS is widely variable but is more common in recipients of myeloablative conditioning, second allo-HCT, prior infection with hepatitis B or C\textsuperscript{4,5} and previous use of gemtuzumab ozogamicin or inotuzumab ozagamicin\textsuperscript{6,7}. Overall, the median incidence is approximately 13\%.\textsuperscript{8} Prevention of SOS is critical for the improvement of allo-HCT outcomes the most accepted prophylaxis strategy is ursodeoxycholic acid or ursodiol. This strategy is associated with reduced proportion of SOS (relative risk 0.34; 95\%CI: 0.17–0.66) and safety profile\textsuperscript{9,10}. However, other studies have failed to demonstrated benefit\textsuperscript{11,12}. Nonetheless, there is no uniform consensus on an effective strategy to prevent SOS\textsuperscript{13,14}.

Low dose unfractionated heparin (UFH) is an SOS prophylaxis strategy, which has been used in allogeneic HCT for decades\textsuperscript{11,15,16}. Randomized-controlled clinical trials and cohort studies evaluating the efficacy of UFH for the prevention of SOS, however, have demonstrated conflicting results\textsuperscript{15,17–22}. These findings may reflect small sample sizes\textsuperscript{19}, delayed introduction of low dose UFH after conditioning\textsuperscript{17}, comparison with historical controls, and lack of a uniform conditioning regimen. Notably, the reported incidence and severity of bleeding associated with UFH in SOS prophylaxis are not significantly worse when compared to non-UFH prophylaxis\textsuperscript{15,21}. Most of the bleeding events associated with UFH have been reported as mild and in some cases moderate\textsuperscript{15,19,21,23}. We therefore analyzed the efficacy and safety of UFH for the prevention of SOS in a large cohort of patients with hematologic malignancies at Memorial Sloan Kettering Cancer Center (MSK). Our evaluation includes recipients of unmodified and CD34+ selected \textit{ex vivo} T-cell depleted (TCD) allogeneic stem cell grafts.

METHODS

Patient and Graft Characteristics

This retrospective analysis included 514 patients who underwent allo-HCT at MSKCC between 01/2003 to 4/2015, follow-up until 10/2021. Patients eligible for this analysis included adults between the ages of 18–75 years, undergoing first allo-HCT for the treatment of hematologic malignancies. Eight-two percent of the patients received CD34+ selected TCD allografts, 13% received unmodified allografts, and only 5% received cord blood grafts. T cell-depletion was the primary graft-versus-host disease (GVHD)
prophylaxis in the first group, whereas unmodified and cord blood transplant groups receive pharmacologic GVHD prophylaxis. Donor-recipient HLA-match was > 8/10, except for cord blood transplants, where patients received either double-unit mismatched cords (one of whom additionally received CD34+ selected, T-cell depleted haploidentical PBSCs on protocol to assess speed of myeloid recovery, NCT01682226). We excluded from the analysis any patient with refractory malignant disease, recipients of reduced intensity or non-myeloablative conditioning, patients who received dual prophylaxis with UFH and ursodiol, or patients on therapeutic anticoagulation at the time of allo-HCT admission. All patients provided written informed consent for transplantation according to the principles of the Declaration of Helsinki, and transplantation outcome analysis was approved by the MSK Institutional Review and Privacy Board.

**Conditioning Regimens, Immunosuppression and SOS Prophylaxis**

Pre-transplant conditioning of these patients was exclusively myeloablative and included busulfan-based and hyperfractionated total body irradiation (TBI) regimens. Other regimens less frequently used were clofarabine/thiotepa/melphalan, carmustine/etoposide/cytarabine/melphalan, and thiotepa/fludarabine/melphalan (Table 1). Patients received either an unmodified stem cell graft from an adult donor, double-unit cord blood graft, or ex-vivo TCD predominantly using CD34+ cell selection of peripheral blood HSC by Isolex™ or Miltenyi™ columns. One patient received double-unit cord blood transplant combined with peripheral blood derived Miltenyi CD34+ selected haplo-identical stem cells. GVHD prophylaxis in unmodified allograft recipients was predominantly with a calcineurin-inhibitor (CNI) and methotrexate. Cord blood transplant recipients received CNI and mycophenolate mofetil. All patients received granulocyte-colony-stimulating factor to promote earlier neutrophil recovery.

All patients received SOS prophylaxis with UFH 100 units/kg/24hrs by continuous intravenous infusion from admission through day +21 or engraftment. The intravenous route was selected over subcutaneous due to practical reasons and to minimize subcutaneous injections in the early post-HCT period. A minority of patients had SOS prophylaxis discontinued at the time of neutrophil engraftment at the discretion of the treating physician. The activated partial thromboplastin time (aPTT) was monitored 3 times per week per institutional standard of care. Thrombocytopenia was not a contraindication for UFH infusion at this low dose. Platelet transfusional threshold was < 10 × 10^9/l per institutional standard of care.

**Study Definitions**

Time to neutrophil recovery was the first of three consecutive days with a sustained absolute neutrophil count (ANC) > 0.5 × 10^9/l and platelet > 20 × 10^9/l, and at least 7 days without platelet transfusion. GVHD was diagnosed clinically with histologic confirmation when appropriate. Acute GVHD was graded according to International Bone Marrow Transplant Registry (IBMTR) severity index, except grades A-D were labeled grades I-IV. Grading was reviewed by a transplant clinician panel to reach consensus of maximum acute GVHD grade by day +100. Transplant-related mortality (TRM) was defined as death from any cause.
in continued remission, and causes of death were assigned according to the algorithm of Copelan et al\textsuperscript{33}.

The Baltimore criteria were used to make the diagnosis of SOS, characterized by bilirubin > 2 mg/dL and at least two other findings of painful hepatomegaly, ascites, and/or weight gain > 5% from baseline\textsuperscript{34}. Severe SOS was defined using Baltimore criteria plus multiorgan failure, defined as creatinine \geq 2 times the baseline at transplant, creatinine clearance \leq 50% level at transplant or dialysis; oxygen saturation \leq 90% or need for positive pressure/ventilator; confusion, lethargy and/or delirium\textsuperscript{35,36}. The measurement of bleeding severity was characterized by using the CTCAE v.4 and included grade 0: no bleeding, grade 1: minor mucosal bleeding or petechiae not requiring packed red blood cells (PRBC); grade 2: any bleeding episode requiring transfusion support of 1–2 units of PRBC/episode in 24 hours; grade 3: any bleeding episode requiring transfusion of > 2 units of PBRC/episode but < 4 units or retroperitoneal bleeding; and grade 4: any bleeding causing hemodynamically instability in a 24h period or any central nervous system bleeding.

**Statistical Analysis**

The MSKCC Adult Bone Marrow Transplant database verified by primary source documents provided patient characteristics and transplant-related outcomes. Cumulative incidence functions estimated neutrophil engraftment, SOS, liver GVHD and NRM. Gray’s test estimated the associations between SOS, patient and graft risk factors. Risk factors evaluated include age (< 40 vs. > 40), hepatitis B and/or C serology pre-HCT (positive vs. negative), donor-recipient HLA-match (10/10 HLA-match vs. < 9/10 HLA-match), graft manipulation (unmodified vs. T-cell depleted).

**RESULTS**

**Patient Demographics**

We evaluated 514 patients. Table 1 summarizes patients’ demographics and graft characteristics. The median age was 52 years (range 21–75). The majority had a diagnosis of acute leukemia or myelodysplastic syndrome (74%), followed by multiple myeloma (11%), lymphoma (9%), and chronic myeloid leukemia/myeloproliferative disorder (6%). A similar number of patients received pre-transplant conditioning with either a busulfan- or TBI-based regimen, and only a minority (3%) had other conditioning regimens. The most common allograft type was \textit{ex vivo} CD34+ selected TCD. Approximately half of the patients were CMV seropositive. Two-thirds received a 10/10 donor-recipient HLA-matched graft (37% related, 35% unrelated) whereas one-third received <9/10 HLA-matched grafts (including CB grafts). The most common GVHD prophylaxis was TCD by CD34+ selection (n = 422; 82%) without other pharmacologic prophylaxis, followed by various CNI based regimens. Only 30 (6%) patients had hepatitis B exposure prior to HSCT, 2 patients had hepatitis B and C exposures, and 7 patients were hepatitis C virus antibody. Most patients had normal liver function test pre-HCT, only 2 patients had a total bilirubin level \geq 2.0 mg/dL.
Low dose unfractionated heparin associated complications

Bleeding complications occurred in 12/514 patients (2.3%). Only 2 (0.4%) patients had significant grade 3 bleeding, and no patient had grade 4 bleeding. One patient developed hemoptysis, requiring admission to the intensive care unit; and another patient had diffuse alveolar hemorrhage. Ten patients had mild, grade 1–2 bleeding complications during UFH prophylaxis. Of those, 5 patients had minor mucosal bleeding or epistaxis, 1 patient had bruising, 3 patients had mild gastrointestinal bleeding, and 1 patient had other minor bleeding.

Sinusoidal Obstructive Syndrome

Strikingly few patients (n = 14, 2.7%) developed hepatic SOS, at a median time of 30 days (range 5–57) post-transplant. Since low dose UFH was discontinued through day +21 or time of neutrophil engraftment, 9 of the 14 patients had SOS prophylaxis completed at the time of SOS diagnosis. The day 100 cumulative incidence of SOS was 3% (95% CI: 2.0–4.0) (Figure 1). The majority were women (n = 10, 71%) and older than 40 years. The most common malignant disease was acute leukemia (n = 10), followed by myelodysplastic syndrome (n = 2), myeloproliferative disease (n = 1), and non-Hodgkin’s lymphoma (n = 1). Eight patients (57%) received myeloablative conditioning with high-dose total body irradiation (TBI), while 5 (36%) had busulfan-based regimen. Only 1 (7%) patient underwent melphalan/fludarabine/thiotepa. Most of the patients who had SOS were recipients of an unrelated donor (n = 11, 79%). Of the 14 pts with SOS, 10 had received an HLA-matched stem cell graft (n = 10), and 4 had received <9/10 HLA-matched grafts. Seven patients received an unmodified adult allograft (6 PBSC, 1 bone marrow), 3 had double-unit CBT grafts, and 4 had TCD grafts. Of the patients who received an unmodified stem cell graft, the most common GVHD prophylaxis regimen was CNI and methotrexate (n = 6, 60%). Eleven of the 14 (78.5%) patients with SOS were CMV seropositive pre-HCT. Two patients (14%) had hepatitis B exposure, and 1 (7%) hepatitis C exposure prior to allo-HCT.

Eight of these 14 patients with SOS received defibrotide therapy, while the remaining 6 received best supportive care. Patients received defibrotide under a clinical trial for VOD/SOS (NCT00628498, NCT00358501, and NCT00003966)37–40. Two patients treated with defibrotide and 5 patients with best supportive care died due to progression to severe hepatic SOS, resulting in multiorgan failure and death. Additionally, 2 patients died due to graft failure, 1 had GVHD, and 1 had malignant disease relapse. Only 3 of the 14 survived SOS.

Analysis of Risk Factors for Day 100 SOS

Univariate analysis was performed to study risk factors of SOS (Table 2). Age, HLA-match, and conditioning regimen were not significant in the univariable analysis. In contrast, patients who received unmodified allografts had a significantly higher incidence of SOS when compared to TCD recipients (11% vs. 1%, p ≤0.001). Similarly, positive hepatitis B and/or C serologies pre-HCT was associated with higher day +100 SOS risk (9% vs. 2%, p = 0.028). Due to the overall few SOS events, adjusted multivariable analysis was not performed.
Hepatic GVHD, Transplant-Related Mortality, and Causes of Death

The day 100 grade II-IV and III-IV liver acute GVHD were 2% (95%CI: 1.0–3.0) and 1% (95%CI: <1.0–2.0), respectively. The incidence of day 100 TRM was 9% (95%CI: 7.0–12.0) whereas 1-year TRM was 16% (95%CI: 13.0–2.0). During the first year post-HCT, 95 patients died of TRM, including infection (n = 37), organ toxicity (n = 27), GVHD (n = 20), graft failure (n = 7), and other (n = 4).

With a median follow-up was 8 years 1 month (range 1–15.5 years), we evaluated long-term outcomes and found that 153 had died of TRM causes at a median of 216 days (range 1 day – 14.3 years). The most common cause of death was infection (n = 58, 38%), followed by GVHD (n = 41, 27%), organ toxicity (n = 31, 20%), graft failure (n = 10, 7%), other/unknown (n = 8, 5%), and secondary malignancies (n = 5, 3%). Causes of death according to stem cell graft were similar, except that infection was more common in TCD recipients whereas GVHD was more common after unmodified allo-HCT.

One hundred and three patients died due to malignant disease relapse or progression at a median time to diagnosis of 239 days (range 30 days – 9.9 years). Patients who relapsed or progressed had acute leukemia (n = 53), multiple myeloma (n = 25), lymphoma (n = 14), and chronic leukemia/myelodysplastic syndrome (n = 12). Of those, 47 patients died between the first year post-HCT.

DISCUSSION

Prevention of hepatic SOS is routinely recommended in allo-HCT\(^4,14\). In the absence of positive prospective randomized clinical trials in adult patients, there is no consensus regarding the length of prophylaxis or drug of choice\(^41\). Currently, ursodeoxycholic acid or ursodiol is widely use given its safety profile, easy route of administration and association with decreased incidence of SOS in several clinical trials\(^9,10\). Additionally, treatment until 90 days post-HCT is associated with reduced proportion of patients with elevated bilirubin levels, severe acute GVHD and liver GVHD\(^12,42\). In our study, we evaluated an alternative SOS prophylaxis using low dose UFH which compared favorably with historical reports using different strategies\(^43\). Hepatic SOS prophylaxis was overall well tolerated and associated with minimal complications despite concurrent thrombocytopenia in the early post allo-HCT period. Hemostasis was routinely monitored by aPTT measurement, and UFH did not affect coagulation time. In fact, if standard clinical tests of coagulation became abnormal, this was an indication to identify a cause other than the low-dose UFH. Bleeding events during UFH prophylaxis occurred in a small number of patients, in the majority of whom it was mild, transient, and self-limited. The few patients who had serious bleeding events were non-fatal and due to causes other than the low dose UFH infusion. Most patients completed UFH prophylaxis as planned and without complications. However, UFH infusion required continuous intravenous access which may limit a wider use of this approach.

We found in this analysis with predominant TCD graft recipients, that age and donor-recipient HLA match had no association with SOS whereas prior hepatitis B or C exposure was associated with increased risk. Recipients of TCD grafts also had a low risk of developing SOS supporting previously reported findings from small series\(^44,45\).
We hypothesize that in the absence of donor derived T-cells, there is less donor-host alloreactivity that may reduce endothelial damage and inflammation to the liver sinusoids. Notably, we observed a late median onset of SOS at day +30 post-HCT. Thus, two third of patients had already completed UFH at the time of SOS diagnosis. This observation suggests that prolonged exposure to SOS prophylaxis beyond day +21 may be considered in select patients including those with high-risk features pre-HCT.

Patients who received UFH had a low incidence of day 100 hepatic GVHD and TRM. The most common cause of death was infection, followed by GVHD. While the incidence of hepatic SOS was low, patients with SOS commonly had multiorgan failure and died. These findings highlight the critical role of optimizing hepatic SOS prophylaxis.

This study is the largest single-center analysis of UFH for the prevention of SOS in allo-HCT, and our results support the use of this parenteral strategy early after allo-HCT. However, our findings may be limited due to the studied population with predominant TCD graft recipients. A prospective multicenter clinical trial exploring the use of defibrotide for the prevention of hepatic SOS in adult and pediatric patients (NCT02851407) have been closed recently due to futility. Which highlights the difficulty of finding an optimal strategy in hepatic SOS prophylaxis. While prospective studies comparing UFH to other prophylaxis methods are warranted, UFH prophylaxis can be prioritized in recipients of conditioning agents that cause severe mucositis, emesis, and/or high-volume diarrhea.

Acknowledgements

This work was supported in part by the National Institutes of Health award number P01 CA23766 and NIH/NCI Cancer Center Support Grant P30 CA008748 by the NCI Core Grant Core Grant (P30 CA008748). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. M.S. was supported by a grant Innovacion tecnologica 2016 from the Sociedad Española de Hematologia y Hemoterapia. We would like to acknowledge the nursing staff, transplant coordinators and Laboratory Medicine staff who greatly contributed to this work.

Data Availability Statement:

The datasets generated during and analyzed during the current study are available from the corresponding author on reasonable request.

References

1. Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant. 2008;41(3):229–237. [PubMed: 17994121]
2. Arai S Long-awaited news for hepatic veno-occlusive disease. Blood. 2016;127(13):1630–1631. [PubMed: 27034420]
3. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118(4):255–267. [PubMed: 8420443]
4. Mohsy M, Malard F, Abeccasis M, Aerts E, Alaskar AS, Aljurf M, et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015;50(6):781–789. [PubMed: 25798682]
5. Carreras E How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. British Journal of Haematology. 2015;168(4):481–491. [PubMed: 25401997]

6. Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102(5):1578–1582. [PubMed: 12738663]

7. Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016;375(8):740–753. [PubMed: 27292104]

8. Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16(2):157–168. [PubMed: 19766729]

9. Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128(12 Pt 1):975–981. [PubMed: 9625683]

10. Ohashi K, Tanabe J, Watanabe R, Tanaka T, Sakamaki H, Maruta A, et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol. 2000;64(1):32–38. [PubMed: 10815785]

11. Park SH, Lee MH, Lee H, Kim HS, Kim K, Kim WS, et al. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29(2):137–143. [PubMed: 11850708]

12. Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remmerger M, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood. 2002;100(6):1977–1983. [PubMed: 12200355]

13. Cheuk DK. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Prophylaxis and treatment controversies. World J Transplant. 2012;2(2):27–34. [PubMed: 24175193]

14. Mohy M, Malard F, Abecasis M, Aerts E, Alaskar AS, Aljurf M, et al. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplant. 2020;55(3):485–495. [PubMed: 31576023]

15. Attal M, Huguet F, Rubie H, Huynh A, Charlet JP, Payen JL, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood. 1992;79(11):2834–2840. [PubMed: 1586733]

16. Forrest DL, Thompson K, Dorcas VG, Couban SH, Pierce R. Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study. Bone Marrow Transplant. 2003;31(12):1143–1149. [PubMed: 12796794]

17. Marsavila L, Gorin NC, Laporte JP, Labopin M, Dupuymontbrun MC, Fouillard L, et al. Prophylactic Heparin Does Not Prevent Liver Venocclusive Disease Following Autologous Bone-Marrow Transplantation. European Journal of Haematology. 1991;47(5):346–354. [PubMed: 1761121]

18. Rosenthal J, Sender L, Secola R, Killen R, Millerick M, Murphy L and Cairo MS. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Bone Marrow Transplantation. 1996;18(1):185–191. [PubMed: 8832013]

19. Feldman L, Milovic V, Jaimovich G, Requejo A, Altclas J, Brioschi S. Prevention of hepatic veno-occlusive disease after bone marrow transplantation (BMT) by continuous infusion of low-dose heparin. Blood. 1996;88(10):3742–3742.

20. Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood. 1998;92(10):3599–3604. [PubMed: 9808553]
21. Simon M, Hahn T, Ford LA, Anderson B, Swinnich D, Baer MR, et al. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin. Bone Marrow Transplant. 2001;27(6):627–633. [PubMed: 11319593]

22. Reiss U, Cowan M, McMillan A, Horn B. Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol. 2002;24(9):746–750. [PubMed: 12468917]

23. Imran H, Tleyjeh IM, Zirakzadeh A, Rodriguez V, Khan SP. Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis. Bone Marrow Transplantation. 2006;37(7):677–686. [PubMed: 16489362]

24. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the Intensity of Conditioning Regimens: Working Definitions. Biology of Blood and Marrow Transplantation. 2009;15(12):1628–1633. [PubMed: 19896087]

25. Assoc WM. World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. Jama-Journal of the American Medical Association. 2013;310(20):2191–2194.

26. Jakubowski AA, Small TN, Young JW, Kernan NA, Castro-Malaspina H, Hsu KC, et al. T cell-depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood. 2007;110(13):4552–4559. [PubMed: 17717135]

27. Keever-Taylor CA, Devine SM, Soiffer RJ, Mendizabal A, Carter S, Pasquini MC, et al. Characteristics of CliniMACS(R) System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. Biol Blood Marrow Transplant. 2012;18(5):690–697. [PubMed: 21875505]

28. Bayraktar UD, de Lima M, Saliba RM, Maloy M, Castro-Malaspina HR, Chen J, et al. Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2013;19(6):898–903. [PubMed: 23467126]

29. Barker JN, Ponce DM, Dahi P, Devlin S, Evans K, Lubin M, et al. Double-Unit Cord Blood (CB) Transplantation Combined with Haplo-Identical CD34+Cells Results in 100% CB Engraftment with Enhanced Myeloid Recovery. Biology of Blood and Marrow Transplantation. 2014;20(2):S138–S139.

30. Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplantation. 2014;49(2):168–173. [PubMed: 23892326]

31. Harnicar S, Ponce DM, Hilden P, Zheng JT, Devlin SM, Lubin M, et al. Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation. Biology of Blood and Marrow Transplantation. 2015;21(5):920–925. [PubMed: 25687796]

32. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. British Journal of Haematology. 1997;97(4):855–864. [PubMed: 9217189]

33. Copelan E, Casper JT, Carter SL, van Burik JA, Hurd D, Mendizabal AM, et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant. 2007;13(12):1469–1476. [PubMed: 18022577]

34. Jones RJ, Lee KSK, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et al. Venoocclusive Disease of the Liver Following Bone-Marrow Transplantation. Transplantation. 1987;44(6):778–783. [PubMed: 3321587]

35. Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, Mcdonald GB. Venoocclusive Disease of the Liver: Development of a Model for Predicting Fatal Outcome after Marrow Transplantation. Journal of Clinical Oncology. 1993;11(9):1729–1736. [PubMed: 8355040]

36. Richardson PG, Murakami C, Jin ZZ, Warren D, Momtaz P, Hoppensteadt D, et al. Multinstitutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-
risk population and factors predictive of outcome. Blood. 2002;100(13):4337–4343. [PubMed: 12393437]

37. Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010;16(7):1005–1017. [PubMed: 20167278]

38. Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127(13):1656–1665. [PubMed: 26825712]

39. Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, et al. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. Biol Blood Marrow Transplant. 2017;23(6):997–1004. [PubMed: 28285079]

40. Kernan NA, Grupp S, Smith AR, Arai S, Triplett B, Antin JH, et al. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Br J Haematol. 2018;181(6):816–827. [PubMed: 29767845]

41. Cheuk DK, Chiang AK, Ha SY, Chan GC. Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2015(5):CD009311. [PubMed: 26017019]

42. Ruutu T, Juvonen E, Remberger M, Remes K, Volin L, Mattsson J, et al. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. Biol Blood Marrow Transplant. 2014;20(1):135–138. [PubMed: 24141008]

43. Dalle JH, Giralt SA. Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment. Biology of Blood and Marrow Transplantation. 2016;22(3):400–409. [PubMed: 26431626]

44. Moscardo F, Sanz GF, de La Rubia J, Jimenez C, Saavedra S, Regadera A, et al. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection. Bone Marrow Transplant. 2001;27(9):983–988. [PubMed: 11436110]

45. Soiffer RJ, Dear K, Rabinowe SN, Anderson KC, Freedman AS, Murray C, et al. Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation. 1991;52(6):1014–1019. [PubMed: 1750063]
Figure 1. Cumulative incidence of hepatic sinusoidal obstruction syndrome. Fourteen patients were diagnosed with hepatic SOS, at a median time of 30 days (range 5–57) post-transplant, day +100 incidence of 3% (95%CI: 2.0–4.0).
Table 1.

Patients Demographics (n = 514).

| Characteristic                  | Patients |
|--------------------------------|----------|
| Median Age (range)              | 52 (21–73)|
| Male gender, n (%)              | 278 (54%)|
| Diagnosis, n (%)                |          |
| Acute leukemia/MDS              | 378 (74%)|
| Lymphoma                        | 44 (9%)  |
| Multiple myeloma                | 5 (11%)  |
| CML/MPD                         | 33 (6%)  |
| Conditioning regimen, n (%)     |          |
| Busulfan-based                  |          |
| Bu/Mel/Flu                      | 231      |
| Bu/Mel                          | 22       |
| Bu/Mel/Thio                     | 2        |
| Bu/Flu                          | 3        |
| Bu/Cy                           | 1        |
| TBI-Based (1320–1375 cGy)       | 239 (46.4%)|
| Flu/Thio/TBI                    | 92       |
| Flu/Cy/TBI                      | 24       |
| Cy/Thio/TBI                     | 119      |
| VP-16/Thio/TBI                  | 2        |
| VP-16/TBI                       | 1        |
| Cy/TBI                          | 1        |
| Clo/Thio/Mel                    | 9 (1.75%)|
| Thio/Flu/Mel                    | 3 (0.6%) |
| Carmustine/VP-16/Cy/Mel         | 3 (0.6%) |
| Melphalan                       | 1 (0.2%) |
| Graft type, n (%)               |          |
| T-cell depletion                | 422 (82%)|
| Unmodified                      | 65 (13%) |
| Cord blood *                    | 27 (5%)  |
| Donor-recipient HLA-match, n (%)|          |
| MRD                             | 189 (37%)|
| MMRD                            | 11 (2%)  |
| MUD                             | 181 (35%)|
| MMUD                            | 106 (21%)|
| Cord blood *                    | 27 (5%)  |

* Cord blood refers to cord blood units with T-cell depletion.
| Characteristic                          | Patients |
|----------------------------------------|----------|
| **Recipient CMV serostatus, n (%)**    |          |
| Negative                               | 233 (45%)|
| Positive                               | 281 (55%)|

| **GVHD prophylaxis, n (%)**            |          |
| T-cell depletion **                    | 422 (82%)|
| CNI/MTX +/- MMF                       | 46 (9%)  |
| CNI/MMF                               | 27 (5%)  |
| CNI +/- MTX +/- sirolimus              | 13 (3%)  |
| No prophylaxis ***                    | 6 (1%)   |

| **History of hepatitis exposure, n (%)** |          |
| Hepatitis B core antibody + or undetermined | 30 (6%)  |
| Hepatitis B core antibody –             | 484 (94%)|
| Hepatitis C virus antibody + ****       | 7 (1%)   |
| Hep C virus antibody –                  | 507 (99%)|

| **Liver function test pre-HCT, n (%)**  |          |
| **Total bilirubin, mg/dL**              |          |
| ≤ 12                                   | 497 (96.6%)|
| 1.3–2.0                                | 15 (3%)   |
| 2.1–2.5                                | 2 (0.4%)  |
| **Aspartate aminotransferase, Units/L** |          |
| ≤ 37                                   | 480 (89%) |
| ULN – 2.5x ULN                         | 4 (1%)    |
| > 2.5 ULN                              | 2 (0.4%)  |
| **Alanine aminotransferase, Units/L**   |          |
| ≤ 55                                   | 484 (94%) |
| ULN – 2.5x ULN                         | 4 (1%)    |
| > 2.5                                  | 26 (5%)   |

N indicates number; MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia; MPD, myeloproliferative disorder; Bu, busulfan; Mel, melphalan; Thio, thiota; Flu, fludarabine; Cy, cyclophosphamide; TBI, total body irradiation; TCD, T-cell depleted; MRD, matched related donor; MMRD, mismatched related donor; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; CMV, cytomegalovirus; GVHD, graft-versus-host disease; CNI, calcineurin inhibitor; MTX, methotrexate; MMF, mycophenolate mofetil; HCT, hematopoietic cell transplant; ULN, upper limit of normal.

* includes 1 recipient of double cord plus haploidentical PBSCs

** Seven T-cell depleted graft recipients required additional GVHD prophylaxis

*** includes 6 patients who received syngeneic allo-HSCT without GVHD prophylaxis

**** includes 2 patients positive for both hepatitis B core antibody and hepatitis C virus antibody
Table 2.
Univariable analysis of variables potentially associated with the 100-day cumulative incidence of SOS.

| Variable                              | 100-day Estimate (95% CI) | p-value |
|---------------------------------------|---------------------------|---------|
| Age (years)                           |                           |         |
| < 40 (n = 117)                        | 3.0 (1.0–6.0)             | 0.6     |
| ≥ 40 (n = 397)                        | 3.0 (1.0–4.0)             |         |
| Donor-recipient HLA-match             |                           | 0.973   |
| 10/10 (n = 370)                       | 3.0 (1.0–5.0)             |         |
| ≤ 9/10 (n = 144)                      | 3.0 (1.0–6.0)             |         |
| Graft                                 |                           | <0.001  |
| TCD (n = 422)                         | 1.0 (<1.0–2.0)            |         |
| Unmodified (n = 92)                   | 11.0 (6.0–18.0)           |         |
| Conditioning regimen                  |                           | 0.414   |
| Busulfan-based (n = 259)              | 2.0 (1.0–4.0)             |         |
| TBI-based (n = 239)                   | 3.0 (2.0–6.0)             |         |
| Other (n = 16)                        |                           |         |
| Recipient hepatitis B and/or C serologies (pre HCT) | | 0.028 |
| Negative (n = 479)                    | 2.0 (1.0–4.0)             |         |
| Positive (n = 35)                     | 9.0 (2.0–21.0)            |         |

HLA indicates human leukocyte antigen; TCD, T-cell depleted; TBI, total body irradiation; allo-HSCT, allogeneic hematopoietic stem cell transplantation.